KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Operating Leases: 2019-2024

Historic Operating Leases for CRISPR Therapeutics AG (CRSP) over the last 6 years, with Dec 2024 value amounting to $206.4 million.

  • CRISPR Therapeutics AG's Operating Leases fell 8.49% to $192.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $192.8 million, marking a year-over-year decrease of 8.49%. This contributed to the annual value of $206.4 million for FY2024, which is 7.44% down from last year.
  • Latest data reveals that CRISPR Therapeutics AG reported Operating Leases of $206.4 million as of FY2024, which was down 7.44% from $223.0 million recorded in FY2023.
  • CRISPR Therapeutics AG's Operating Leases' 5-year high stood at $228.2 million during FY2022, with a 5-year trough of $50.1 million in FY2020.
  • For the 3-year period, CRISPR Therapeutics AG's Operating Leases averaged around $219.2 million, with its median value being $223.0 million (2023).
  • Per our database at Business Quant, CRISPR Therapeutics AG's Operating Leases skyrocketed by 325.17% in 2021 and then fell by 7.44% in 2024.
  • Over the past 5 years, CRISPR Therapeutics AG's Operating Leases (Yearly) stood at $50.1 million in 2020, then skyrocketed by 325.17% to $212.9 million in 2021, then rose by 7.19% to $228.2 million in 2022, then fell by 2.27% to $223.0 million in 2023, then declined by 7.44% to $206.4 million in 2024.